Holdings
Avidity Partners Management LP
As of Sep 30, 2026, Avidity Partners Management LP reported 16 positions worth US$427M. Largest: Dianthus Therapeutics, Inc., CG Oncology, Inc. and Oruka Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Dianthus Therapeutics, Inc. | 1.9M | US$167M | −205K | Sep 30, 2026 |
| CG Oncology, Inc. | 1.35M | US$95.6M | −50,000 | Sep 30, 2026 |
| Oruka Therapeutics, Inc. | 785K | US$65.4M | +25,000 | Sep 30, 2026 |
| Jade Biosciences, Inc. | 2M | US$28.1M | +299K | Sep 30, 2026 |
| Enliven Therapeutics, Inc. | 550K | US$25.2M | no change | Sep 30, 2026 |
| Perspective Therapeutics, Inc. | 6.07M | US$16.7M | −232K | Sep 30, 2026 |
| Aktis Oncology, Inc. | 484K | US$9.43M | no change | Sep 30, 2026 |
| Immunic, Inc. | 670K | US$6.23M | no change | Sep 30, 2026 |
| Mobia Medical, Inc. | 325K | US$3.07M | −474K | Sep 30, 2026 |
| Palvella Therapeutics, Inc. | 20,000 | US$2.76M | −50,000 | Sep 30, 2026 |